A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors

Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy

(2013) Devron R. Shah et al.   DRUG SAFETY

The effect of cost on adherence to prescription medications in Canada

(2012) M. R. Law et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs

(2012) Saroj Niraula et al.   JOURNAL OF CLINICAL ONCOLOGY

Hurdles in anticancer drug development from a regulatory perspective

(2012) Bertil Jonsson et al.   Nature Reviews Clinical Oncology

Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies

(2012) Nicholas S. Downing et al.   NEW ENGLAND JOURNAL OF MEDICINE

Additional safety risk to exceptionally approved drugs in Europe?

(2011) Arna H. Arnardottir et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe

(2011) Samantha A. Roberts et al.   HEALTH AFFAIRS

Evaluation of Oncology Drugs at the European Medicines Agency and US Food and Drug Administration: When Differences Have an Impact on Clinical Practice

(2011) Francesco Trotta et al.   JOURNAL OF CLINICAL ONCOLOGY

Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

(2011) Hans-Georg Eichler et al.   NATURE REVIEWS DRUG DISCOVERY

Conditional Approval and Approval Under Exceptional Circumstances as Regulatory Instruments for Stimulating Responsible Drug Innovation in Europe

(2010) W P C Boon et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?

(2010) Anne Mason et al.   JOURNAL OF CLINICAL ONCOLOGY

Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers

(2010) Hans-Georg Eichler et al.   NATURE REVIEWS DRUG DISCOVERY

Examination of the Relationship Between Oncology Drug Labeling Revision Frequency and FDA Product Categorization

(2009) Robert J. Berlin   AMERICAN JOURNAL OF PUBLIC HEALTH

Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?

(2009) Elizabeth A. Richey et al.   JOURNAL OF CLINICAL ONCOLOGY

Drug-Review Deadlines and Safety Problems

(2008) Daniel Carpenter et al.   NEW ENGLAND JOURNAL OF MEDICINE